Abbeville

Bronchiectasis is a chronic lung disease involving permanent widening of parts of the airways, leading to mucus buildup, infections, and ongoing inflammation. Researchers are evaluating whether using the SIMEOX device at home, combined with remote physiotherapy, can improve quality of life and reduce lung flare-ups compared to enhanced standard care in patients with non-cystic fibrosis bronchiectasis. This study focuses on long-term effects over about two years. Participants will be randomly assigned to one of two groups one receiving standard care plus remote physiotherapy, and the other using the SIMEOX device daily at home along with remote physiotherapy and standard care. The SIMEOX device delivers short pulses of negative air pressure through a mouthpiece to help loosen and move mucus from the lungs. Remote physiotherapy sessions occur once a month for the first three months and then every three months thereafter. During the study, participants will be monitored for changes in quality of life using questionnaires at 6, 12, and 24 months, and the number of lung exacerbations over about 24 months will be recorded. Lung function tests spirometry will also be conducted periodically. Researchers will track treatment adherence, hospitalizations, and any adverse events. The total study duration per participant is around two years, with regular assessments to evaluate the impact of the SIMEOX device combined with physiotherapy.

Researchers are evaluating the use of a low-protein diet LPD with specially designed low-protein foods called FLAVIS in patients with chronic kidney disease CKD stages 3A to 5 who are not on dialysis. The study aims to compare this approach to a standard low-protein diet without these low-protein foods to see if it helps patients better manage their protein intake and potentially improve their quality of life. This trial is randomized and controlled, led by Dr. Schr AG SPA, following the 2020 KDOQI nutrition guidelines for CKD. Participants are randomly assigned to one of two groups one will follow a low-protein diet according to current practice, while the other will follow the same diet but with the addition of FLAVIS low-protein products. The intervention group will receive FLAVIS products to include in their diet. The study tracks dietary adherence, protein intake, and other health measures over a 12-month period. During the study, participants will attend scheduled visits at baseline, 1, 3, 6, 9, and 12 months. Researchers will monitor protein intake, diet compliance, body mass index BMI, weight, body composition, blood and urine markers, diabetic glycemic profiles, patient quality of life, and satisfaction with the diet. Safety will be assessed by tracking adverse events throughout the 12 months. Participants will complete diet records and self-administered questionnaires as part of the data collection process.